


Response after Non-final Rejection  
USSN 10/715,666

Attorney Docket R0144B-REG

CLAIM LISTING:

1. (Original) A compound of the formula:



or a pharmaceutically acceptable salt thereof,  
wherein

R<sup>1</sup> is hydrogen or alkyl;

R<sup>2</sup> is alkyl, haloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkylalkyl, heteroalkylsubstituted cycloalkyl, heterosubstituted cycloalkyl, heteroalkyl, cyanoalkyl, heterocyclyl, heterocyclylalkyl, or -Y<sup>1</sup>-C(O)-Y<sup>2</sup>-R<sup>11</sup> (where Y<sup>1</sup> and Y<sup>2</sup> are independently either absent or an alkylene group and R<sup>11</sup> is hydrogen, alkyl, haloalkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino);


R<sup>3</sup> is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterosubstituted cycloalkyl, heterocyclyl, aryl, aralkyl, haloalkyl, heteroalkyl, cyanoalkyl, -alkylene-C(=O)-R<sup>4</sup> (where R<sup>4</sup> is hydrogen, alkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino), or acyl;

Ar<sup>1</sup> is aryl;

X<sup>1</sup> is O, NR<sup>5</sup> or S, where R<sup>5</sup> is hydrogen or alkyl; and

X<sup>2</sup> is a bond, O, NR<sup>6</sup>, S or CH<sub>2</sub>, where R<sup>6</sup> is hydrogen or alkyl.

2. (Original) The compound according to Claim 1 of the formula:



3. (Original) The compound according to Claim 2, wherein X<sup>1</sup> is O.

Response after Non-final Rejection  
USSN 10/715,666

Attorney Docket R0144B-REG

4. (Original) The compound according to Claim 3, wherein  $R^1$  is hydrogen.
5. (Original) The compound according to Claim 4, wherein  $R^3$  is hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl.
6. (Original) The compound according to Claim 5, wherein  $R^3$  is alkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl.
7. (Original) The compound according to Claim 4, wherein  $R^2$  is heteroalkyl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl, heteroaryl or aryl.
8. (Original) The compound according to Claim 7, wherein  $R^2$  is optionally substituted phenyl.
9. (Currently amended) The compound according to Claim 8, wherein  $R^2$  is heterocyclylphenyl, alkylthiophenyl, alkylsulfinylphenyl, alkylsulfonylphenyl, phenyl, halophenyl, hydroxyphenyl, acylphenyl, cyanophenyl, alkoxy carbonylphenyl, carboxamidophenyl, N-alkylcarboxamidophenyl, N,N-dialkylcarboxamidophenyl, alkylsulfonyloxyphenyl, carbamoylphenyl, N-alkylcarbamoylphenyl or N,N-dialkylcarbamoylphenyl
10. (Original) The compound according to Claim 9, wherein  $R^3$  is alkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl.
11. (Original) The compound according to Claim 7, wherein  $Ar^1$  is 2-halophenyl, 4-halophenyl, 2,4-dihalophenyl, 2,6-dihalophenyl, 2-alkylphenyl, 1-alkoxyphenyl, 2-alkoxyphenyl, 4-alkoxyphenyl, 3,5-dialkoxyphenyl, 2-halo-5-alkoxyphenyl or 2-dialkylamino-6-fluorophenyl.
12. (Original) The compound according to Claim 2, wherein  $R^1$  is hydrogen.
13. (Original) The compound according to Claim 12, wherein  $R^2$  is heteroalkyl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl, heteroaryl or aryl.

Response after Non-final Rejection  
USSN 10/715,666

Attorney Docket R0144B-REG

14. (Original) The compound according to Claim 13, wherein  $R^3$  is hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl.
15. (Original) The compound according to Claim 14, wherein  $Ar^1$  is 2-halophenyl, 4-halophenyl, 2,4-dihalophenyl, 2,6-dihalophenyl, 2-alkylphenyl, 1-alkoxyphenyl, 2-alkoxyphenyl, 4-alkoxyphenyl, 3,5-dialkoxyphenyl, 2-halo-5-alkoxyphenyl or 2-dialkylamino-6-fluorophenyl.
16. (Original) The compound according to Claim 1, wherein  $X^2$  is a bond or  $CH_2$ .
17. (Original) The compound according to Claim 16, wherein  $R^3$  is hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl.
18. (Original) The compound according to Claim 17, wherein  $R^1$  is hydrogen.
19. (Original) The compound according to Claim 18, wherein  $R^2$  is heteroalkyl, heterocyclyl, or heterosubstituted cycloalkyl.
20. (Original) The compound according to Claim 19, wherein  $X^1$  is O.
21. (Original) A composition comprising:
  - (a) a compound of Claim 1; and
  - (b) a pharmaceutically acceptable excipient.
22. (Original) A method for treating a p38 MAP kinase mediated disorder comprising administering to a patient in need of such treatment, an effective amount of a compound of Claim 1.
23. (Original) The method of Claim 22, wherein the p38 mediated disorder is arthritis, Crohn's disease, inflammatory bowel disease, adult respiratory distress syndrome, or chronic obstructive pulmonary disease.

Response after Non-final Rejection  
 USSN 10/715,666


Attorney Docket R0144B-REG

24. (Original) The method of Claim 22, wherein the p38 mediated disorder is Alzheimer's disease.


25. (Currently amended) A method for treating an FGFR kinase mediated disorder comprising administering to a patient in need of such treatment, an effective amount of a compound of Claim 1, wherein said FGFR kinase mediated disorder comprises atherosclerosis.

26. (canceled).

27. (Original) A method for producing a compound of the formula:



said method comprising the steps of contacting a compound of the formula:



with an amine compound of the formula  $R^1R^2NH$  to produce a compound of Formula.

wherein

$R^1$  is hydrogen or alkyl;

$R^2$  is alkyl, haloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkylalkyl, heteroalkylsubstituted cycloalkyl, heterosubstituted cycloalkyl, heteroalkyl, cyanoalkyl, heterocyclyl, heterocyclalkyl or  $-Y^1-C(O)-Y^2-R^{11}$  (where  $Y^1$  and  $Y^2$  are independently either absent or an alkylene group and  $R^{11}$  is hydrogen, alkyl, haloalkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino);

$R^3$  is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, aryl, aralkyl, haloalkyl, heteroalkyl, cyanoalkyl,  $-alkylene-C(=O)-R^4$  (where  $R^4$  is hydrogen, alkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino) or acyl;

$Ar^1$  is aryl;

Response after Non-final Rejection  
USSN 10/715,666

Attorney Docket R0144B-REG

$X^1$  is O,  $NR^5$  or S, where  $R^5$  is hydrogen or alkyl;  
 $X^2$  is a bond, O,  $NR^6$ , S or  $CH_2$ , where  $R^6$  is hydrogen or alkyl;  
 $n$  is an integer from 0 to 2; and  
 $R^7$  is an alkyl group.

28. (Original) The method of Claim 27 wherein:

$R^1$  is hydrogen;  
 $R^2$  is heteroalkyl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl, heteroaryl or aryl;  
 $R^3$  is hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl;  
 $Ar^1$  is aryl;  
 $X^1$  is O;  
 $X^2$  is a bond; and  
 $n$  is 1 or 2.

29. (Canceled)

30. (Original) The compound of claim 10, wherein  $R^3$  is methyl.

31. (Original) The compound of claim 30, wherein  $R^2$  is 4-(morpholin-4-yl)phenyl.

32. (Original) The compound of claim 31, wherein  $Ar^1$  is 2-bromophenyl.

33. (Original) The compound of claim 31, wherein  $Ar^1$  is 2,6-dichlorophenyl.

34. (Original) The compound of claim 30, wherein  $R^2$  is 3-methylsulfinylphenyl.

35. (Original) The compound of claim 34, wherein  $Ar^1$  is 2-bromophenyl.

\* \* \* \* \*